Top Page
Medical Developments International Limited
(Sydney:MVP)
Medical Developments International Limited (MVP) vs. iShares MSCI Australia ETF (EWA)
Medical Developments International Limited Business Overview & Revenue Model
Medical Developments International Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.06M | 39.06M | 33.15M | 32.34M | 21.94M | 25.27M |
| Gross Profit | 29.43M | 29.43M | 24.37M | -2.52M | -3.06M | 16.67M |
| EBITDA | 1.67M | 1.67M | -29.45M | -4.28M | -12.86M | -11.11M |
| Net Income | 94.00K | 94.00K | -40.99M | -5.61M | -12.41M | -12.56M |
Balance Sheet | ||||||
| Total Assets | 66.40M | 66.40M | 59.16M | 109.49M | 101.36M | 100.17M |
| Cash, Cash Equivalents and Short-Term Investments | 17.84M | 17.84M | 9.73M | 24.66M | 20.40M | 36.28M |
| Total Debt | 1.99M | 1.99M | 2.29M | 2.56M | 2.81M | 3.05M |
| Total Liabilities | 11.29M | 11.29M | 13.43M | 28.17M | 44.06M | 31.87M |
| Stockholders Equity | 55.10M | 55.10M | 45.73M | 81.31M | 57.30M | 68.30M |
Cash Flow | ||||||
| Free Cash Flow | -486.00K | -486.00K | -13.95M | -24.16M | -15.94M | -15.37M |
| Operating Cash Flow | -43.00K | -43.00K | -10.78M | -16.50M | -10.72M | -8.81M |
| Investing Cash Flow | -1.04M | -1.04M | -3.17M | -7.67M | -5.21M | -6.56M |
| Financing Cash Flow | 8.68M | 8.68M | -807.00K | 28.06M | 142.00K | 36.12M |
Medical Developments International Limited Technical Analysis
Medical Developments International Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$41.75M | 11.67 | 7.64% | 3.23% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$77.73M | 690.00 | 0.19% | ― | 17.82% | ― | |
41 Neutral | AU$19.03M | -1.28 | ― | ― | -47.30% | 82.53% | |
39 Underperform | AU$4.26M | 16.00 | ― | ― | 69.59% | ― | |
39 Underperform | AU$24.81M | -3.16 | -35.58% | ― | 45.30% | -24.18% |
Medical Developments International Limited Corporate Events
Medical Developments International Limited announced a change in the director’s interest, with Director Russell Basser acquiring 40,000 fully paid ordinary shares, increasing his total holdings to 55,873 shares. This acquisition, conducted through an on-market trade, reflects a significant investment by the director, potentially indicating confidence in the company’s future prospects and stability, which may positively influence stakeholder perceptions.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited announced the availability of a recording of its 2025 Annual General Meeting. This release, authorized by the Board of Directors, provides stakeholders with insights into the company’s operations and strategic direction, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried out successfully by poll. The outcomes indicate strong shareholder support for the company’s current direction, which may positively impact its future operations and industry positioning.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
At the 2025 Annual General Meeting, MVP’s Chair, Gordon Naylor, announced his departure with Mark Fladrich set to assume the role in December. The company reported a significant improvement in its financials for FY25, with an 18% increase in revenue and a modest net profit after tax. MVP plans to deploy recently raised funds to support its growth strategy, while also enhancing governance and management systems. The transition in leadership is expected to bring fresh perspectives, crucial for the company’s continued growth.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited reported a strong financial performance for Q1 FY26, with a $1.9 million increase in Penthrox revenue and a 26% growth in its Australian hospital segment. The company is progressing with approvals for the Penthrox paediatric label in Europe, aiming to expand its market. Despite seasonal softness in its respiratory segment, MVP has managed to improve cash from operating activities and maintain a healthy cash balance of $16.1 million. The company plans to invest in growth initiatives to solidify Penthrox as a standard of care, which may result in softer short-term earnings but is expected to enhance long-term financial performance.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited announced a change in the director’s interest, with Director Mark Fladrich acquiring 62,858 fully paid ordinary shares on the market as of September 30, 2025. This acquisition reflects a strategic move that could impact the company’s market positioning and stakeholder interests, highlighting the director’s confidence in the company’s future prospects.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited announced a change in the director’s interest, with Director Paul Townsend acquiring 25,000 fully paid ordinary shares on the market, valued at $16,785.31. This acquisition reflects an increase in the director’s stake in the company, potentially indicating confidence in the company’s future performance and impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited announced the appointment of Mr. Mark Fladrich as the new Chair of the Board, effective December 1, 2025, succeeding Mr. Gordon Naylor. Mr. Fladrich, with over 30 years of experience in the pharmaceutical industry, is expected to bring significant commercial and strategic expertise to the company, particularly in pain management. This leadership transition is anticipated to strengthen MVP’s market position and support the company’s strategic objectives, including the growth of Penthrox. Additionally, the Board has created a Deputy Chair role, appointing Mr. Paul Townsend, to further enhance governance.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited reported a significant improvement in financial performance for the fiscal year ending June 30, 2025, with an 18% increase in revenue and a modest net profit after tax. The company successfully raised funds to support its growth strategy and plans to deploy these resources strategically in the coming year. The maturation of governance and management systems has led to measurable improvements, and the company expresses gratitude to its employees and shareholders for their support during challenging times.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited has announced its 2025 Annual General Meeting, scheduled for October 10, 2025, at 1 pm AEDT. The meeting will be conducted in a hybrid format, allowing both in-person and virtual attendance via the Computershare platform. Shareholders are encouraged to submit proxy forms as per the instructions provided. This approach reflects the company’s commitment to accessibility and engagement with its stakeholders, potentially impacting shareholder participation and company transparency.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited reported a significant improvement in its financial performance for the fiscal year 2025, achieving a net profit after tax of $0.1 million compared to a loss of $41.0 million in the previous year. The company’s revenue increased by $5.9 million, driven by higher pricing, cost efficiencies, and volume growth, particularly in the Australian and European markets. The approval of Penthrox for pediatric use by the Health Products Regulatory Agency is expected to expand its market reach in Europe. Additionally, the successful transition of Penthrox distribution in France and Switzerland to new partners and continued growth in the US respiratory spacer market highlight the company’s strategic focus on expanding its global footprint.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited reported an 18% increase in revenue to $39.1 million for the year ending June 2025, driven by strong growth in its Pain Management segment and improved pricing strategies. The company achieved a net profit after tax of $0.1 million, a significant turnaround from the previous year’s loss. Key highlights include a 23% revenue increase in Pain Management, driven by volume growth in Australia and Europe, and a 9% increase in Respiratory revenue, with strong performance in the US market. The company also reported improved operating cash flow and free cash flow, alongside continued global penetration of Penthrox, particularly in Europe and Australia. Despite these positive results, no dividends were declared for the current or previous year.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited has released its FY25 full-year results, providing insights into its operational performance and strategic direction. The announcement highlights the company’s commitment to maintaining its market position through ongoing product development and adapting to market conditions, which may have significant implications for its stakeholders.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Ltd has announced that its Annual General Meeting will take place on October 10, 2025. A key agenda item will be the election of Directors, with nominations closing on August 27, 2025. This meeting is significant for stakeholders as it involves the election of leadership that will influence the company’s strategic direction and operations.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Ltd is set to announce its financial results for the fiscal year ending 30 June 2025 on 21 August 2025. The announcement will be followed by a webcast for investors featuring the CEO and CFO, indicating the company’s commitment to transparency and stakeholder engagement. This financial disclosure is crucial for understanding MVP’s operational performance and strategic positioning in the emergency medical solutions market.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.